Bernstein Lowers Nuvalent, Inc. Rating to Hold
Bernstein downgraded Nuvalent, Inc. to a hold rating with a $124 price target, a 0.35% upside from the current price.
Key Points
- On June 24, 2026, Bernstein downgraded Nuvalent, Inc. to a hold rating, setting a price target of $124.
- Bernstein's $124 price target implies 0.35% upside from Nuvalent, Inc.'s ($NUVL) current $123.57 share price.
- Shares of Nuvalent, Inc. traded near $123.44 on Wednesday, with a market cap of about $9.77 billion.
- Insiders, including Cameron Wheeler and Anna Protopapas, bought 3,444 shares each on June 16, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 24, 2026, Bernstein downgraded Nuvalent, Inc. (NasdaqGS: NUVL) to a hold rating, setting a price target of $124. This move comes as the stock traded around $123.44 on Wednesday.
Bernstein vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Nuvalent, Inc.
Institutional investors have been active in Nuvalent, Inc. DEERFIELD MANAGEMENT COMPANY, L.P. maintained its position with 17,248,450 shares valued at approximately $1.77 billion. FMR LLC reduced its holdings by 1,577,925 shares, now holding 9,274,959 shares worth about $950.22 million, a 14.5% decrease. PARADIGM BIOCAPITAL ADVISORS LP slightly increased its stake by 55,000 shares to 5,324,433 shares, valued at $545.49 million. BLACKROCK, INC. added 19,524 shares, bringing its total to 4,824,785 shares worth roughly $494.30 million. JPMORGAN CHASE & CO significantly increased its holdings by 883,098 shares, ending with 3,088,349 shares valued at $298.71 million, marking a 40% increase.
Nuvalent, Inc. Stock Snapshot
Shares of Nuvalent, Inc. traded near $123.44 on Wednesday. The company has a market cap of about $9.77 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is 1.153, indicating moderate volatility. Over the past year, the stock has seen a low of $71.13 and a high of $123.62. Its 50-day moving average is $105.64, and the 200-day moving average is $99.67. The company has a strong liquidity position with a current ratio of 16.14 and a quick ratio of 15.89.
$NUVL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Nuvalent, Inc. reported a net margin of 0.0% and a return on equity of -41.2%. Earnings per share were -$6.06, reflecting the company's current unprofitable status. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Nuvalent, Inc.
Several insiders at Nuvalent, Inc. made purchases on June 16, 2026. Cameron Wheeler, Anna Protopapas, Grant Bogle, Sapna Srivastava, Ron Squarer, and Michael Meyers each bought 3,444 shares. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, Bernstein downgraded Nuvalent, Inc. to a hold rating with a $124 price target. Other firms, including TD Cowen, Barclays, UBS, Guggenheim, Wells Fargo, HC Wainwright & Co., and Wedbush, have also downgraded the stock to hold with the same price target. The consensus among analysts is a hold rating with a mean target price of $128.13 based on 16 analyst opinions.
About Nuvalent, Inc.
Nuvalent, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing therapies for cancer patients, particularly those with treatment-resistant tumors. The company is working on several drug candidates, including Zidesamtinib and Neladalkib, aimed at treating non-small cell lung cancer and other conditions. Nuvalent partners with Guardant Health, Inc. to develop companion diagnostics and was founded in 2017.
Bottom Line
Bernstein's downgrade of Nuvalent, Inc. to a hold rating with a $124 price target reflects a cautious stance amid the company's ongoing development efforts. Investors closely watch such analyst actions, as they provide insights into market sentiment and company prospects. It's important to remember that these analyst ratings are based on past performance and future projections, which can change.
Get Nuvalent, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NUVL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.